The risk of developing a severe PE during short flights remains extremely low, because it occurs only once per million ...

The Cellares Cell Shuttle platform was the first to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, which offers partners additional touchpoints and priority review mechanisms ...

Autolus Therapeutics plc , a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first Integrated ...

The American Association for the Study of Liver Diseases and Infectious Diseases Society of America have updated guidance on ...

Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for ...

A prospective validation study found that age-adjusted D-dimer thresholds can safely rule out lower extremity DVT for more ...

An oncology pharmacist shares how a treatment takes a different approach to treating chronic graft-versus-host disease (GVHD) ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

Peter Voorhees, MD, emphasizes the importance of carefully determined early regimens for smoldering myeloma and involving ...

Learn how to rapidly identify, manage, and prevent drowning injuries using updated evidence-based approaches from prehospital care to ICU management.

Autolus will evaluate Cellares' fully automated, high-throughput manufacturing platform in preparation for expansion into new indications Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage ...

Coronary artery disease characterized by vascular calcification poses significant challenges in the field of interventional ...